{"id":"mp-513","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4594369","moleculeType":"Small molecule","molecularWeight":"345.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MP-513 blocks the C5a receptor on immune cells, preventing the recruitment and activation of neutrophils and other inflammatory cells downstream of complement cascade activation. This mechanism reduces tissue damage and inflammation in complement-driven diseases, particularly those affecting the kidney and other organs.","oneSentence":"MP-513 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:06.922Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"IgA nephropathy"},{"name":"C3 glomerulopathy"}]},"trialDetails":[{"nctId":"NCT02220907","phase":"PHASE3","title":"Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2014-08","conditions":"Type 2 Diabetes Mellitus","enrollment":153},{"nctId":"NCT00971243","phase":"PHASE2","title":"Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-08","conditions":"Type 2 Diabetes Mellitus","enrollment":448},{"nctId":"NCT02354235","phase":"PHASE3","title":"Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":138},{"nctId":"NCT02354222","phase":"PHASE3","title":"Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":154},{"nctId":"NCT00974090","phase":"PHASE3","title":"Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-09","conditions":"Type 2 Diabetes Mellitus","enrollment":194},{"nctId":"NCT01026194","phase":"PHASE3","title":"Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-12","conditions":"Type 2 Diabetes Mellitus","enrollment":204},{"nctId":"NCT02314637","phase":"PHASE3","title":"Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-08","conditions":"Type 2 Diabetes Mellitus","enrollment":240},{"nctId":"NCT00628212","phase":"PHASE2","title":"Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-01","conditions":"Type 2 Diabetes","enrollment":324},{"nctId":"NCT00998881","phase":"PHASE3","title":"Monotherapy Study of MP-513 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-09","conditions":"Type 2 Diabetes Mellitus","enrollment":203},{"nctId":"NCT02081599","phase":"PHASE4","title":"Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2014-01","conditions":"Type 2 Diabetes Mellitus","enrollment":148},{"nctId":"NCT01072331","phase":"PHASE3","title":"Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2010-02","conditions":"Type 2 Diabetes Mellitus","enrollment":99},{"nctId":"NCT01301833","phase":"PHASE3","title":"Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-02","conditions":"Type 2 Diabetes Mellitus","enrollment":462},{"nctId":"NCT03787017","phase":"PHASE1","title":"A Study to Compare MP-513 20mg & Metformin XR 1000mg FDC With Coadministration of the Two Separate Drugs","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2014-01","conditions":"Healthy Volunteers","enrollment":36},{"nctId":"NCT03787043","phase":"PHASE1","title":"A Study to Evaluate the Effect of Food on Fixed-Dose Combination of MP-513 10 mg and Metformin XR 750 mg","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2014-05","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT01805830","phase":"PHASE3","title":"Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2012-05","conditions":"Type 2 Diabetes","enrollment":189},{"nctId":"NCT01798238","phase":"PHASE3","title":"Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2012-11","conditions":"Type 2 Diabetes Mellitus","enrollment":142}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MP-513","genericName":"MP-513","companyName":"Tanabe Pharma Corporation","companyId":"tanabe-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MP-513 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation. Used for IgA nephropathy, C3 glomerulopathy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}